• Combined Genetic and Clinical Data Do Not Improve Determination of Risk for Esophageal Adenocarcinoma

Combined Genetic and Clinical Data Do Not Improve Determination of Risk for Esophageal Adenocarcinoma

Addition of genetic information to clinical factors does not increase identification of individuals at risk for esophageal adenocarcinoma, researchers report in the January 2019 issue of Gastroenterology. New screening and risk evaluation methods are needed to improve early detection of esophageal adenocarcinoma, because most patients receive a diagnosis at a late

Read more
  • Surgical vs Endoscopic Treatment of T1 Esophageal Adenocarcinoma?

Surgical vs Endoscopic Treatment of T1 Esophageal Adenocarcinoma?

Endoscopic therapy of T1a esophageal adenocarcinoma (EAC) yields more quality-adjusted life years (QALYs) and is more cost effective than esophagectomy, shows a Markov model analysis published in the March issue of Clinical Gastroenterology and Hepatology. However, therapy for T1b EAC should be selected based on patients’ age and comorbidities. Although EAC has

Read more
  • Can Statin Use After Diagnosis of Esophageal Cancer Prolong Survival?

Can Statin Use After Diagnosis of Esophageal Cancer Prolong Survival?

Statin use after a diagnosis of esophageal adenocarcinoma, but not esophageal squamous cell carcinoma, reduces esophageal cancer–specific and all-cause mortality, researchers report in the April issue of Gastroenterology. Esophageal cancer is the fifth most common cause of cancer-related death in men and eighth most common cause in women, worldwide. Esophageal

Read more

What is the Best Treatment for Esophageal Adenocarcioma?

Patients with esophageal adenocarcinoma (EAC) who receive endoscopic therapy survive as long as patients treated by surgery, according to the November issue of Clinical Gastroenterology and Hepatology. Esophageal cancer is a highly fatal malignancy—approximate 19% of patients survive 5 years. The incidence of EAC, the most common form of esophageal

Read more